Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label, Multicenter Study of ZL-1218 as a Single Agent and as Combination Therapy With Anti-PD-1 Antibody to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects With Advanced Solid Tumor Malignancies

NCT05859464 is registered in ClinicalTrials.gov with Zai Lab (Hong Kong), Ltd. as lead sponsor.

NCT NCT05859464
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05859464 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label, Multicenter Study of ZL-1218 as a Single Agent and as Combination Therapy With Anti-PD-1 Antibody to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects With Advanced Solid Tumor Malignancies
Lead sponsor
Zai Lab (Hong Kong), Ltd.
Phase
Phase 1
Overall status
Terminated
Start date
July 24, 2023
Completion date
August 28, 2025
Enrollment
34 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

malignant solid tumor